ORG Partners’s Sagimet Biosciences SGMT Stock Holding History

ORG Partners’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,611	Closed	-$43K	–	1342
2024 Q2	$43K	Buy	+13,611	New	+$62.4K	0.01%	839

Other funds holding SGMT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

ORG Partners's SGMT Position: Q3 2024 in Review

ORG Partners sold out of Sagimet Biosciences (SGMT) in Q3 2024, closing a stake of 13,611 shares — an estimated $43K sold.

ORG Partners first reported a position in SGMT in Q2 2024 and held it in 1 quarter. The position peaked at $43K in Q2 2024. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2024.

ORG Partners reported no remaining Sagimet Biosciences position as of Q3 2024 after selling out during the quarter.
ORG Partners sold 13,611 Sagimet Biosciences shares in Q3 2024, an estimated $43K.
ORG Partners first reported a position in Sagimet Biosciences in Q2 2024 and held it in 1 quarter.
ORG Partners's Sagimet Biosciences position peaked at $43K in Q2 2024.
63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.